Considerations and development of topical microbicides to inhibit the sexual transmission of HIV
- 1 August 2002
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 11 (8), 1077-1097
- https://doi.org/10.1517/13543784.11.8.1077
Abstract
The increased incidence of HIV/AIDS disease in women aged 15 - 49 years has identified the urgent need for a female-controlled, efficacious and safe vaginal topical microbicide. To meet this challenge, new topical microbicide candidates consisting of molecules or formulations that modify the genital environment (BufferGel, engineered Lactobacillus, over-the-counter lubricants), surfactants (C31D/Savvy, sodium dodecyl sulfate, sodium lauryl sulfate), polyanionic polymers (PRO 2000, beta-cyclodextrin, Carraguard, CAP, D2S, SPL-7013), proteins (cyanovirin-N, monoclonal antibodies, thromspondin-1 peptides, Pokeweed antiviral protein and others), reverse transcription inhibitors (PMPA [Tenofovir ]), UC-781, SJ-3366, DABO and thiourea) and other molecules (NCp7-specific virucides, chemokine receptor agonists/antagonists, WHI-05 and WHI-07) are currently being investigated for activity, safety and efficacy. This review will assess the development of these molecules in the context of cervicovaginal defences and the clinical failure of nonoxynol-9.Keywords
This publication has 99 references indexed in Scilit:
- Mutations associated with genotypic resistance to antiretroviral therapy in treatment naı̈ve HIV-1 infected patients in GreeceVirus Research, 2002
- Mechanism of Thrombospondin-1 Anti-HIV-1 ActivityAIDS Patient Care and STDs, 2000
- Resistance of the Human Immunodeficiency Virus to the Inhibitory Action of Negatively Charged Albumins on Virus Binding to CD4AIDS Research and Human Retroviruses, 1999
- Persistence of Human Immunodeficiency Virus in Semen After Adding Indinavir to Combination Antiretroviral TherapyClinical Infectious Diseases, 1999
- Design of a “Microbicide” for Prevention of Sexually Transmitted Diseases Using “Inactive” Pharmaceutical ExcipientsBiologicals, 1999
- The Thiocarboxanilide Nonnucleoside UC781 Is a Tight-Binding Inhibitor of HIV-1 Reverse TranscriptaseBiochemistry, 1997
- Cell-mediated infection of cervix derived epithelial cells with primary isolates of human immunodeficiency virusArchiv für die gesamte Virusforschung, 1996
- Anti-HIV effect of gramicidin in vitro: Potential for spermicide useLife Sciences, 1994
- Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.Proceedings of the National Academy of Sciences of the United States of America, 1994
- A Synthetic Peptide from HIV-1 gp41 Is a Potent Inhibitor of Virus-Mediated Cell—Cell FusionAIDS Research and Human Retroviruses, 1993